UniQure Aiming To Be First With Hemophilia B Gene Therapy
Presenting 12 Month Data At ASH
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
You may also be interested in...
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.